TekniPlex Healthcare to Open New Production Facility in Madison, WI

200,000-sq-ft ISO 13485-certified production plant will significantly expand capacity of its engineered barrier products for flexible packaging in pharmaceutical, medical device and diagnostic applications

TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, is substantially extending its North American footprint and expanding global capacity with a new 200,000-square-foot manufacturing plant in Madison, Wisconsin – the second TekniPlex Healthcare facility in the city. Scheduled to open in early 2024, the new facility will operate under the ISO 13485:2016 quality management system, which certifies the ability to provide medical devices and related services that consistently meet customer and regulatory requirements.

TekniPlex Healthcare’s new facility will feature sophisticated new manufacturing equipment that will significantly boost the company’s lamination capacity for a broad range of materials including PET, nylon, paper, foil, PE, EAA and ionomer, in both peelable and non-peelable structures. This will help drive shorter lead-times and ensure best in class quality. The laminate and coated products are utilized in a wide variety of applications for the medical device, pharmaceutical, and diagnostics end markets, including flexible foil and plastic pouches, contact lens packaging, blisters and blister lidding, and sterilizable protective structures for medical devices, accessories and procedural tools.

“Our business has grown substantially across the medical device, pharmaceutical and diagnostics sectors, and the new Wisconsin location will help TekniPlex provide our customers access to the most advanced process technology and available capacity, solidifying our industry-leading quality and delivery,” said Chris Qualters, CEO of TekniPlex Healthcare. “In addition to providing highly engineered products to ensure patient safety and outcomes, this facility also offers enhancement of our business continuity planning – a highly attractive benefit in an industry where supply risk mitigation is essential to guarantee lifesaving products are available when they are needed.”

The plant will feature new coating and lamination assets, boosting capacity for a wide range of products, including coated Tyvek® and reinforced papers. The plant also will showcase new flexographic printing capability, adding to TekniPlex’s set of solutions. The high-definition printer features fast changeover to expedite customer delivery times and creates an almost zero waste scenario in the production environment.

All newly installed equipment will utilize the state-of-the-art technology to reduce energy consumption and process waste. Combined with a factory-wide trim waste recovery system, this will allow the plant to maximize its environmental efficiency.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”